The immunopotentiating effects of shark-derived protein hydrolysate

Nutrition

Volumn 30, Issue 6, 2014, Pages 706-712

  Mallet, Jean François ^a   Duarte, Jairo ^a   Vinderola, Gabriel ^b   Anguenot, Raphaël ^c   Beaulieu, Martin ^c   Matar, Chantal ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^c InnoVactiv inc   (Canada)

Author keywords

Enterotoxigenic E. coli infection; Immunomodulation; Intestinal mucosa; Shark derived protein hydrolysate

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN HYDROLYSATE; SHARK DERIVED PROTEIN HYDROLYSATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOPOTENTIATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; ESCHERICHIA COLI INFECTIONS; IMMUNOLOGY; INFLAMMATION; ORAL DRUG ADMINISTRATION; SHARK;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EPITHELIAL CELLS; ESCHERICHIA COLI INFECTIONS; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; PROTEIN HYDROLYSATES; SHARKS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84899739020     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2013.10.025     Document Type: Article

References (51)

1. Stefano G.B., Salzet M. Invertebrate opioid precursors: evolutionary conservation and the significance of processing. Int Rev Cytol 1999, 187:261-286.
2. Iwaniak A., Minkiewicz P. Proteins as the source of physiologically and functionally active peptides. ACTA Sci Pol Technol Aliment 2007, 3:5-15.
3. Erdmann K., Cheung B.W.Y., Schröder H. The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease. J Nutr Biochem 2008, 19:643-654.
4. Kristinsson H.G., Rasco B.A. Biochemical and functional properties of Atlantic salmon (Salmo salar) muscle proteins hydrolyzed with various alkaline proteases. J Agric Food Chem 2000, 48:657-666.
5. Kristinsson H.G., Rasco B.A. Fish protein hydrolysates: production, biochemical, and functional properties. Crit Rev Food Sci Nutr 2000, 40:43-81.
6. Erdmann K., Grosser N., Schipporeit K., Schröder H. The ACE inhibitory dipeptide Met-Tyr diminishes free radical formation in human endothelial cells via induction of heme oxygenase-1 and ferritin. J Nutr 2006, 136:2148-2152.
7. Kim S.-K., Wijesekara I. Development and biological activities of marine-derived bioactive peptides: a review. J Funct Foods 2010, 2:1-9.
8. Shahidi F., Zhong Y. Bioactive peptides. J AOAC Int 2008, 91:914-931.
9. Samaranayaka A.G.P., Kitts D.D., Li-Chan E.C.Y. Antioxidative and angiotensin-I-converting enzyme inhibitory potential of a Pacific Hake (Merluccius productus) fish protein hydrolysate subjected to simulated gastrointestinal digestion and Caco-2 cell permeation. J Agric Food Chem 2010, 58:1535-1542.
10. Cook M.T., Hayball P.J., Birdseye L., Bagley C., Nowak B.F., Hayball J.D. Isolation and partial characterization of a pentraxin-like protein with complement-fixing activity from snapper (Pagrus auratus, Sparidae) serum. Dev Comp Immunol 2003, 27:579-588.
11. Balti R., Bougatef A., El-Hadj Ali N., Zekri D., Barkia A., Nasri M. Influence of degree of hydrolysis on functional properties and angiotensin I-converting enzyme-inhibitory activity of protein hydrolysates from cuttlefish (Sepia officinalis) by-products. J Sci Food Agric 2010, 90:2006-2014.
12. De Leo F., Panarese S., Gallerani R., Ceci L.R. Angiotensin converting enzyme (ACE) inhibitory peptides: production and implementation of functional food. Curr Pharm Des 2009, 15:3622-3643.
13. Duarte J., Vinderola G., Ritz B., Perdigón G., Matar C. Immunomodulating capacity of commercial fish protein hydrolysate for diet supplementation. Immunobiology 2006, 211:341-350.
14. Simpson E. Special regulatory T-cell review: regulation of immune responses-examining the role of T cells. Immunology 2008, 123:13-16.
15. Fitzgerald A.J., Rai P.S., Marchbank T., Taylor G.W., Ghosh S., Ritz B.W., et al. Reparative properties of a commercial fish protein hydrolysate preparation. Gut 2005, 54:775-781.
16. Waldron M.R., Kulick A.E., Bell A.W., Overton T.R. Acute experimental mastitis is not causal toward the development of energy-related metabolic disorders in early postpartum dairy cows. J Dairy Sci 2006, 89:596-610.
17. Günther J., Petzl W., Zerbe H., Schuberth H.-J., Koczan D., Goetze L., et al. Lipopolysaccharide priming enhances expression of effectors of immune defence while decreasing expression of pro-inflammatory cytokines in mammary epithelia cells from cows. BMC Genomics 2012, 13:17.
18. Adler-Nissen J. Enzymatic hydrolysis of proteins for increased solubility. J Agric Food Chem 1976, 24:1090-1093.
19. Gregory S.H., Sagnimeni A.J., Wing E.J. Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J Immunol 1996, 157:2514-2520.
20. Slorach E.M., Campbell F.C., Dorin J.R. A mouse model of intestinal stem cell function and regeneration. J Cell Sci 1999, 112:3029-3038.
21. Allen K.P., Randolph M.M., Fleckenstein J.M. Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic escherichia coli strains. Infect Immun 2006, 74:869-875.
22. Vinderola G., Perdigón G., Duarte J., Farnworth E., Matar C. Effects of the oral administration of the products derived from milk fermentation by kefir microflora on immune stimulation. J Dairy Res 2006, 73:472-479.
23. Vinderola G., Matar C., Perdigón G. Milk fermented by Lactobacillus helveticus R389 and its non-bacterial fraction confer enhanced protection against Salmonella enteritidis serovar Typhimurium infection in mice. Immunobiology 2007, 212:107-118.
24. Meisel H. Biochemical properties of peptides encrypted in bovine milk proteins. Curr Med Chem 2005, 12:1905-1919.
25. Piva M., Moreno J.I., Jenkins F.S., Smith J.K.A., Thomas J.L., Montgomery C., et al. Invitro modulation of cytokine expression by enkephalin-derived peptides. Neuroimmunomodulation 2005, 12:339-347.
26. Shimizu M., Son D.O. Food-derived peptides and intestinal functions. Curr Pharm Des 2007, 13:885-895.
27. LeBlanc J.-G., Matar C., Valdéz J.C., LeBlanc J., Perdigon G. Immunomodulating effects of peptidic fractions issued from milk fermented with Lactobacillus helveticus. J Dairy Sci 2002, 85:2733-2742.
28. Vinderola G., Perdigón G., Duarte J., Farnworth E., Matar C. Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranofaciens on the gut mucosal immunity. Cytokine 2006, 36:254-260.
29. De Moreno de LeBlanc A., Matar C., LeBlanc N., Perdigón G. Effects of milk fermented by Lactobacillus helveticus R389 on a murine breast cancer model. Breast Cancer Res 2005, 7:R477-R486.
30. Rachid M., Matar C., Duarte J., Perdigón G. Effect of milk fermented with a Lactobacillus helveticus R389(+) proteolytic strain on the immune system and on the growth of 4 T1 breast cancer cells in mice. FEMS Immunol Med Microbiol 2006, 47:242-253.
31. LeBlanc J., Fliss I., Matar C. Induction of a humoral immune responsefollowing an Escherichia coli O157:H7 infection with an immunomodulatory peptidic fraction derived from Lactobacillus helveticus-fermented milk. Clin Diagn Lab Immunol 2004, 11:1171-1181.
32. Vinderola G., Matar C., Perdigón G. Role of intestinal epithelial cells in immune effects mediated by Gram-positive probiotic bacteria: involvement of toll-like receptors. Clin Diagn Lab Immunol 2005, 12:1075-1084.
33. Vinderola G., Duarte J., Thangavel D., Perdigón G., Farnworth E., Matar C. Immunomodulating capacity of kefir. J Dairy Res 2005, 72:195-202.
34. Cao Q., Wang Y., Zheng D., Sun Y., Wang Y., Lee V.W.S., et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J Am Soc Nephrol 2010, 21:933-942.
35. Taylor A., Verhagen J., Akdis C.A., Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int Arch Allergy Immunol 2004, 135:73-82.
36. De Moreno de LeBlanc A., Matar C., Perdigón G. The application of probiotics in cancer. Br J Nutr 2007, 98(Suppl 1):S105-S110.
37. Lorea Baroja M., Kirjavainen P.V., Hekmat S., Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007, 149:470-479.
38. Shen J., Sakaida I., Uchida K., Terai S., Okita K. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci 2005, 77:1502-1515.
39. Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000, 68:437-446.
40. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol 2001, 1:983-993.
41. Canellada A., Blois S., Gentile T., Margni Idehu R.A. Invitro modulation of protective antibody responses by estrogen, progesterone and interleukin-6. Am J Reprod Immunol 2002, 48:334-343.
42. Van Anders S.M. Gonadal steroids and salivary IgA in healthy young women and men. Am J Hum Biol Off J Hum Biol Counc 2010, 22:348-352.
43. De Moreno de LeBlanc A., Perdigón G. Yogurt feeding inhibits promotion and progression of experimental colorectal cancer. Med Sci Monit Int Med J Exp Clin Res 2004, 10:BR96-104.
44. De Moreno de LeBlanc A., Chaves S., Carmuega E., Weill R., Antóine J., Perdigón G. Effect of long-term continuous consumption of fermented milk containing probiotic bacteria on mucosal immunity and the activity of peritoneal macrophages. Immunobiology 2008, 213:97-108.
45. Doyle S.L., O'Neill L.A.J. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006, 72:1102-1113.
46. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25:5467-5484.
47. Yang X.O., Chang S.H., Park H., Nurieva R., Shah B., Acero L., et al. Regulation of inflammatory responses by IL-17 F. J Exp Med 2008, 205:1063-1075.
48. Chang S.H., Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17 F regulates inflammatory responses. Cell Res 2007, 17:435-440.
49. Prause O., Bossios A., Silverpil E., Ivanov S., Bozinovski S., Vlahos R., et al. IL-17-producing T lymphocytes in lung tissue and in the bronchoalveolar space after exposure to endotoxin from Escherichia coli invivo-effects of anti-inflammatory pharmacotherapy. Pulm Pharmacol Ther 2009, 22:199-207.
50. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., Fontenot J., Castelli L., Ye X., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28:546-558.
51. Petzl W., Günther J., Pfister T., Sauter-Louis C., Goetze L., von Aulock S., et al. Lipopolysaccharide pretreatment of the udder protects against experimental Escherichia coli mastitis. Innate Immun 2012, 18:467-477.